Alnylam Puts Up $65M To End Tekmira Trade Secrets Battle

Law360, New York (November 13, 2012, 6:55 PM EST) -- Alnylam Pharmaceuticals Inc. has agreed to pay $65 million to Tekmira Pharmaceuticals Corp. as part of a licensing agreement settling a lawsuit that accused it of misappropriating Tekmira's trade secrets related to gene-silencing therapeutics, the companies announced Monday.

The Cambridge, Mass.-based Alnylam agreed to make the payment to Tekmira within 10 days, a sum comprised of $35 million to terminate previous licensing agreements between the two companies and $30 million to secure rights for Alnylam to produce its own lipid nanoparticle technology, or LNP, products in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.